Charles River Laboratories International (NYSE:CRL) Hits New 52-Week Low – Time to Sell?

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) hit a new 52-week low during trading on Monday . The company traded as low as $157.69 and last traded at $159.07, with a volume of 100569 shares trading hands. The stock had previously closed at $163.79.

Wall Street Analyst Weigh In

A number of analysts have commented on CRL shares. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research note on Monday, February 3rd. UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Morgan Stanley reduced their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Evercore ISI upped their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Finally, The Goldman Sachs Group lowered their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Down 3.1 %

The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market capitalization of $7.92 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The company’s fifty day moving average is $178.90 and its 200-day moving average is $192.24.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Versant Capital Management Inc lifted its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International during the third quarter valued at $32,000. Pinnacle Bancorp Inc. increased its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the period. Assetmark Inc. boosted its position in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Finally, Tortoise Investment Management LLC boosted its position in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 115 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).